Class / Patent application number | Description | Number of patent applications / Date published |
514375000 | Polycyclo ring system having the oxazole ring as one of the cyclos | 53 |
20080207713 | Compositions and Methods For Enhancing Nitric Oxide Delivery - The present invention is directed to compounds, combinations, compositions and methods for enhancing nitric oxide (NO) delivery to target sites, and in particular to muscle, both normal and dystrophic. Enhanced NO delivery according to the present invention may be achieved by using a combination of a muscle relaxant and an NO donor compound, or by using a compound of the invention: formula (I) wherein R | 08-28-2008 |
20080249147 | Emulsion-Stabilized Preparation - It is intended to provide a medicinal composition having a high biological availability and a process for producing the same which comprises dispersing a drug component in two or more surfactants (for example, surfactants belonging to the same series such as a long-chain fatty acid glyceride having a long-chain polyoxyethylene in its hydrophilic group with a medium-chain fatty acid glyceride having a short-chain polyoxyethylene in its hydrophilic group), adding a small amount of water thereto to give a semisolid or liquid medicinal composition in the form of a microemulsion, and producing an oral preparation such as capsules by using the same so as to form and sustain a stable microemulsion containing the drug component (in particular, a hardly water-soluble drug component) in the digestive tract. | 10-09-2008 |
20080280963 | New amino-alkyl-amide derivatives as CCR3 receptor ligands - The invention relates to a compound of the general formula (I), | 11-13-2008 |
20080300288 | Alkenyldiarylmethanes, Fused Analogs And Syntheses Thereof - Non-nucleoside inhibitors of HIV-1 reverse transcriptase are described. Such inhibitors may be used as part of a combination therapy to treat HIV infection. Compounds described herein exhibit antiviral potency. In addition, compounds described herein exhibit metabolic stability. Also described herein are processes for preparing Non-nucleoside inhibitors of HIV-1 reverse transcriptase. | 12-04-2008 |
20090012137 | ANTMICROBIAL AND RADIOPROTECTIVE COMPOUNDS - The present invention relates to a method of treatment and/or prophylaxis of a microbial infection, comprising the step of administering an effective amount of a compound of formula (I), in which X and Y are either the same or different and selected from a heteroatom; is a double or single bond depending on the heteroatoms X and Y; R | 01-08-2009 |
20090018174 | MACROLIDES AS ANTI-INFLAMMATORY AGENTS - Provided herein are macrolide derivatives that can be useful in treating or preventing inflammatory diseases. Also provided are pharmaceutical compositions comprising one or more macrolide derivatives optionally together with one or more pharmaceutically acceptable carriers, excipients, diluents or mixtures thereof, as well as methods for treating or preventing inflammatory diseases. | 01-15-2009 |
20090048314 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY - Provided are polymorphic forms of a compound useful in the treatment of Duchenne muscular dystrophy. | 02-19-2009 |
20090149519 | PHENYLAMINO-BENZOXAZOLE SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THEIR PRODUCTION AND USE THEREOF AS MEDICAMENTS - This invention relates to a compound of formula I, | 06-11-2009 |
20090239920 | PHARMACEUTICAL FORMULATIONS OF AN ANHYDRATE CRYSTAL FORM OF 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL - The present invention is directed to pharmaceutical formulations of an anhydrate crystal form of an estrogen receptor modulator, and pharmaceutical compositions and preparative processes thereof. | 09-24-2009 |
20090258917 | Benzoxazoles Useful in the Treatment of Inflammation - There is provided the use of a compound of formula I, | 10-15-2009 |
20090275626 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROGENIC PAIN - The purpose of the present invention is to provide agents useful for the prevention or treatment of a neuropathic pain. That is, the present invention provides agents for the prevention or treatment of neuropathic pain such as painful diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, or postoperative or posttraumatic chronic pain or the like, which comprises a β | 11-05-2009 |
20100004301 | Benzoxazoles Useful in the Treatment of Inflammation - There is provided the use of a compound of formula I, | 01-07-2010 |
20100022607 | DIAZONAMIDE ANALOGS - Novel diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided. | 01-28-2010 |
20100035946 | INDOLINE ANTI-CANCER AGENTS - Indoline compounds having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided. | 02-11-2010 |
20100035947 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES - A method for manufacturing neuraminic acid derivatives is provided, also synthetic intermediates of the neuraminic acid derivatives and methods for their manufacture, and neuraminic acid derivatives having high purity. | 02-11-2010 |
20100076039 | COMPOSITION FOR THE PREVENTION AND TREATMENT OF METABOLIC DISORDER CONTAINING BENZAZOLE DERIVATIVES AS AN ACTIVE INGREDIENT - Disclosed is a composition for the prevention and treatment of metabolic diseases, which comprises a benzazole derivative as an active ingredient. The benzazole derivative has inhibitory activity against DGAT (diacylglycerol acyltransferase), which causes metabolic diseases such as obesity and diabetes in the process of lipid metabolism. With the ability to effectively control lipid metabolism and energy metabolism, thus, the composition is useful in the prevention and treatment of metabolic diseases, such as obesity and diabetes. | 03-25-2010 |
20100076040 | Method For Producing Bisbenzoxazoles - The invention relates to a method for producing bisbenzoxazoles that are interconnected by means of a system of conjugated double bonds, according to which o-aminophenols are reacted with dicarboxylic acids, the carboxyl groups of which are interconnected via a double bond or a system of conjugated double bonds, to form an ammonium salt, said ammonium salt being converted in the presence of dehydrogenating catalysts and solvents with a low dielectric loss into benzoxazol by means of microwave radiation. | 03-25-2010 |
20100113541 | CRYSTAL FORMS OF 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL - The present invention is directed to monohydrate and anhydrate crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol, an estrogenic receptor modulator useful in the treatment of, for example, diseases related to abnormal levels of estrogen. | 05-06-2010 |
20100173960 | The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases - The invention relates generally to novel compositions and methods comprising one or more cyclohexanehexol and one or more NSAID. The compositions and methods provide beneficial effects in the treatment and prevention of diseases involving a disorder in protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence, in particular neurodegenerative diseases. | 07-08-2010 |
20100173961 | BENZOOXAZOL-2-ONE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS - The invention relates to benzooxazol-2-one derivatives of general formula (I) with the meanings indicated in the description, the pharmaceutically usable salts thereof, and the use thereof as medicinal substances. | 07-08-2010 |
20110053995 | BENZENESULFONANILIDE COMPOUND INHIBITORS OF UREA TRANSPORTERS - Provided herein are small molecule compounds that alter the transport activity of solute transporters, particularly urea transporters. The compounds described herein belong to the benzenesulfonanilide class of compounds. The compounds described herein are useful for increasing solute clearance in states of fluid overload and for treating cardiovascular, renal, and metabolic diseases, disorders, and conditions. Methods for identifying and using these agents that inhibit urea transporters are described herein. | 03-03-2011 |
20110065762 | METHODS OF USE OF ANTIVIRAL COMPOUNDS - The present invention relates, in part, to methods of treatment, prevention, and inhibition of viral disorders. In one aspect, the present invention relates to inhibition of the M2 proton channel of influenza viruses (e.g. influenza A virus) and other similar viroporins (e.g., VP24 of Ebola and Marburg viruses; and NS3 protein of Bluetongue). The present invention further relates, inter alia, to compounds which have been shown to possess antiviral activity, in particular, inhibiting the M2 proton channel of influenza viruses. | 03-17-2011 |
20110190360 | PYRAZOLO[5,1B]OXAZOLE DERIVATIVES AS CRF-1 RECEPTOR ANTAGONISTS - There are described 4-difluoromethoxyphenyl pyrazolo[5.1-b]oxazole derivatives of Formula I: | 08-04-2011 |
20110190361 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF - The present invention provides a compound represented by the formula | 08-04-2011 |
20110230531 | THERAPEUTIC COMPOUNDS - The invention provides compounds of formula (I) wherein A, B, R | 09-22-2011 |
20120065237 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES - Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods are disclosed. | 03-15-2012 |
20120071527 | THERAPEUTIC COMPOUNDS - The invention provides compounds of formula I: | 03-22-2012 |
20120165377 | AGENT FOR REDUCING VISCERAL FAT WEIGHT - An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): | 06-28-2012 |
20120196907 | Diazonamide Analogs - Novel diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided. | 08-02-2012 |
20120208856 | Heterocyclic Benzoxazole Compositions as Inhibitors of Hepatitis C Virus - This invention relates to benzoxazole compounds, compositions and devices for delivering them, processes for manufacturing them, and methods of using them in the treatment of Hepatitis C Virus. | 08-16-2012 |
20120245209 | HETEROCYCLIC SULFONAMIDE DERIVATIVES - The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds have been demonstrated as inhibitors of MEK and therefore may be useful in the treatment of hyperproliferative diseases (e.g., cancer and inflammation). | 09-27-2012 |
20120295942 | Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists - There are described 4-difluoromethoxyphenyl pyrazolo[5.1-b]oxazole derivatives useful as corticotropin releasing factor (CRF | 11-22-2012 |
20120302613 | NOVEL ANTIBIOTICS - The invention relates generally to novel antibiotics and their analogs, to processes for the preparation of these novel antibiotics, to pharmaceutical compositions comprising the novel antibiotics; and to methods of using the novel antibiotics to treat or inhibit various disorders. | 11-29-2012 |
20130030029 | Glucagon Antagonists - Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co-crystals and prodrugs thereof. Formula I | 01-31-2013 |
20130303578 | PHENYLAMINO-BENZOXAZOLE SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THEIR PRODUCTION AND USE THEREOF AS MEDICAMENTS - This invention relates to a compound of formula I, | 11-14-2013 |
20140080876 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS - The present invention relates to a method of treatment and/or prophylaxis of a microbial infection, comprising the step of administering an effective amount of a compound of formula (I), in which X and Y are either the same or different and selected from a heteroatom; is a double or single bond depending on the heteroatoms X and Y; R | 03-20-2014 |
20140142148 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES - A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems. | 05-22-2014 |
20140163078 | Mycobacterial Disease Detection, Treatment, and Drug Discovery - Methods for detecting and treating | 06-12-2014 |
20140163079 | DIPHOSPHATE MIMETICS AND USES THEREOF - The present invention provides compounds of Formulae (I)-(V), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. In one aspect, compounds of the present invention are useful as glycosyltransferase inhibitors, in particular, O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) inhibitors. In another aspect, compounds of the present invention are useful as kinase inhibitors, in particular, PLK1 inhibitors, GSK3P inhibitors, or MAPKAPK2 inhibitors. The present invention further provides methods of using the inventive compounds, e.g., as biological probes to study the inhibition of OGT and/or kinase activity and as therapeutics, e.g., for the treatment of OGT-associated and/or kinase-associated conditions. | 06-12-2014 |
20150018398 | METHODS OF USING ESTROGEN RECEPTOR-BETA LIGANDS AS RADIATION MITIGATORS - Disclosed herein are methods useful for treating radiation damage in a subject. | 01-15-2015 |
20150031735 | SOLID FORMS OF A TRANSTHYRETIN DISSOCIATION INHIBITOR - The present invention relates to solid forms of the N-methyl-D-glucamine (meglumine) salt of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one solid form and to the therapeutic or prophylactic use of such solid forms and compositions. | 01-29-2015 |
20150045402 | HETEROCYCLIC ACETAMIDE COMPOUND - A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like. | 02-12-2015 |
20150057320 | TRANSTHYRETIN LIGANDS CAPABLE OF INHIBITING RETINOL-DEPENDENT RBP4-TTR INTERACTION FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION, STARGARDT DISEASE, AND OTHER RETINAL DISEASE CHARACTERIZED BY EXCESSIVE LIPOFUSCIN ACCUMULATION - A method for treating a disease characterized by excessive lipofuscin accumulation in the retina of a mammal afflicted therewith comprising administering to the mammal an effective amount of a transthyretin (TTR) ligand. | 02-26-2015 |
20150087680 | GLUCAGON ANTAGONISTS - Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co-crystals and prodrugs thereof. Formula I | 03-26-2015 |
20150111935 | NOVEL 1,3-BENZOXAZOL-2(3H)-ONES AND THEIR USE AS MEDICAMENTS AND COSMETICS - The present invention relates to a novel class of 1,3-benzoxazol-2(3H)-ones and their use as a medicament, preferably as a dermatologic agent, and as a cosmetic. These novel compounds are particularly useful in treating and/or preventing inflammation, irritation, itching, pruritus, pain, oedema and/or pro-allergic or allergic conditions in a patient. Usually they are topically applied to the skin or mucosa in the form of a pharmaceutical or cosmetic composition comprising the compound and a pharmaceutically and/or cosmetically acceptable carrier. | 04-23-2015 |
20150126567 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FAMILIAL AMYLOID POLYNEUROPATHY - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of familial amyloid polyneuropathy may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of transthyretin-related hereditary amyloidosis, neurodegenerative diseases, amyloidosis, neuropathic pain, amyloid fibril formation and cardiomyopathy related diseases. | 05-07-2015 |
20150297572 | Calcium Flux Agonists And Methods Therefor - Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca | 10-22-2015 |
20150344447 | NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION - The present invention is directed to compounds of formula (A): | 12-03-2015 |
20160030396 | METHODS FOR TREATING RESPIRATORY DISEASES AND FORMULATIONS THEREFOR - Compounds, compositions, methods, and uses are described herein for the treatment of respiratory diseases, including cystic fibrosis. Inhalation formulations of macrolide antibiotics are also described herein. The treatment of bacterial infections continues to be an important endeavor of pharmaceutical research and development. The specter of bacterial resistance to currently available antibiotics is ever-present, and accordingly, new and improved compounds, pharmaceuticals formulations, treatment methods, and treatment protocols are needed. | 02-04-2016 |
20160039916 | TRANSTHYRETIN ANTIBODIES AND USES THEREOF - The present invention provides compositions comprising anti-transthyretin antibodies. The compositions are particularly useful for diagnosis, prognosis and/or treatment of amyloid diseases or symptoms thereof. | 02-11-2016 |
20160136138 | DRUG FOR TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE - The present invention provides a compound useful in the prevention and treatment of nonalcoholic fatty liver disease. The invention relates to a drug for the prevention and/or treatment of nonalcoholic fatty liver disease, the drug having as an active ingredient (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate of these. | 05-19-2016 |
20180022695 | GLUCAGON ANTAGONISTS | 01-25-2018 |
20180022797 | TRANSTHYRETIN ANTIBODIES AND USES THEREOF | 01-25-2018 |